Freenome Patents

Patent portfolio assigned to Freenome (verified via public assignee records). Liquid-biopsy / multiomics cancer-screening company (went public via SPAC, ticker FRNM, Dec 2025). Competitors are blood-based CRC/MCED peers. 'Customers' modeled as commercial partners: Exact Sciences (exclusive US license for CRC blood test) and Roche (ex-US commercialization), both from Freenome's own newsroom. has_patents=true: Freenome Holdings, Inc. is an assignee on Google Patents (e.g. WO2019200410A1); exact count not reliably confirmed, patent_count_estimate left 0/null.